What is Prokarium?
Prokarium is a biopharmaceutical firm at the forefront of microbial immunotherapy, developing novel cancer treatments using a proprietary bacterial strain. Their primary focus is on bladder cancer, with aspirations to revolutionize treatment paradigms for significant unmet medical needs. The company's 'Living Cures' platform is designed to deliver programmable therapeutics across various cancers, aiming to amplify the effectiveness of existing immunotherapies. Prokarium's strategic direction targets healthcare providers and patients seeking advanced therapeutic options.
How much funding has Prokarium raised?
Prokarium has raised a total of $66.7M across 4 funding rounds:
Series A
$10M
Other Financing Round
$5.7M
Series B
$21M
Other Financing Round
$30M
Series A (2018): $10M, investors not publicly disclosed
Other Financing Round (2019): $5.7M led by Wellcome Trust
Series B (2020): $21M supported by Riyadh Valley Company, Flerie Invest, Korea Investment Partners, and Future Fund
Other Financing Round (2023): $30M, investors not publicly disclosed
Key Investors in Prokarium
Riyadh Valley Company
Riyadh Valley Company, the investment arm of King Saud University, focuses on nurturing student and entrepreneurial ventures by providing capital and strategic guidance. They aim to transform innovative ideas into successful businesses, fostering growth through their support platforms.
Wellcome Trust
Wellcome Trust is a global charitable foundation dedicated to supporting discovery research and addressing urgent health challenges. They provide grants, foster partnerships, and engage in advocacy to improve global health outcomes through scientific advancement.
Korea Investment Partners
Korea Investment Partners is a notable investment entity, though specific details on their focus areas are not provided in this context. They participate in funding rounds, contributing capital to companies across various sectors.
What's next for Prokarium?
The substantial enterprise-level funding and recent strategic investment indicate Prokarium is poised for accelerated development and market penetration. This capital infusion is expected to fuel the advancement of their lead bladder cancer program and further expand the capabilities of their Living Cures platform. The company's trajectory suggests a move towards scaling operations, potentially initiating clinical trials, and solidifying partnerships within the oncology sector. Prokarium's focus on innovative microbial immunotherapies positions it as a key player in the evolving landscape of cancer treatment.
See full Prokarium company page
